PLoS ONE · 2019 · 25 citations · 17 references
Veterinary MedicineInfectious DiseasesAntimicrobial ResistanceInfectious Disease EpidemiologyMedical MicrobiologyAntibiotic ResistanceAntimicrobial Susceptibility TestingBacterial EpidemiologyBacterial InfectionsResistance EpidemiologyResistance SurveillanceAntibiotic Susceptibility Data AnalysisAntimicrobial Resistance PatternsAntimicrobial Susceptibility InterpretationDrug Resistance PatternsEpidemiologic Data AnalysisResistance BreakpointsShigella ResistanceShigellosis Surveillance
BACKGROUND: Shigellosis is the second leading cause of diarrheal death globally. The global burden has been complicated by the emergence of Shigella strains resistant to first line antibiotic treatments such as ciprofloxacin. This study aims to describe the epidemiologic distribution of the most common Shigella species, and their antimicrobial susceptibility patterns to ciprofloxacin and nalidixic acid (NA) in Latin America. METHODS: Laboratory data from 19 countries were obtained through the Latin American Network for Antimicrobial Resistance Surveillance (ReLAVRA) from 2000-2015. The Clinical Laboratory Standards Institute reduced susceptibility breakpoints for Enterobacteriaceae was used to interpret the disc diffusion tests for Shigella susceptibility to ciprofloxacin and NA. Negative binominal regression was used to analyze longitudinal trends of Shigella isolates antimicrobial susceptibility. RESULTS: 79,548 Shigella isolates were tested and reported between 2000-2015. The most common isolated species were S. flexneri (49%), and S. sonnei (28%). There was a steady increase in the proportion of S. sonnei isolates within the region(p<0.001). The average annual percentage increase (AAPI) in nonsusceptibility was 18.4% (p<0.001) for ciprofloxacin (baseline = 0.3); and 13.2%(p<0.001) for NA (baseline = 3). AAPI nonsusceptibility to ciprofloxacin was 13.3% for S. flexneri (p<0.04); and 39.9% for S. sonnei (p<0.001). Honduras, Dominican Republic, Venezuela, and Chile reported the highest increase in nonsusceptibility to ciprofloxacin among all Shigella isolates. CONCLUSION: There is an increasing trend in Shigella nonsusceptibility to ciprofloxacin and NA, including among the most common shigella species, in Latin America. This rise of nonsusceptibility among Shigella species to commonly used treatments such as ciprofloxacin is alarming and threatens the control and management of this currently treatable infection. Improved data quality, collection and reporting is needed in Latin America to respond effectively to the rising trends observed. This includes the need for quality isolate level epidemiological data; molecular data, and data on antibiotic consumption and use.
17
Performance standards for antimicrobial susceptibility testing
Mary Jane Ferraro · 2001 · 9.8K citations
Christopher Troeger, Mohammad H. Forouzanfar, Puja C Rao et al. · The Lancet Infectious Diseases · 2017 · 1.4K citations · Full text
Peter Collignon, John J. Beggs, Timothy R. Walsh et al. · The Lancet Planetary Health · 2018 · 755 citations · Full text
Christopher Troeger, Brigette F. Blacker, Puja C Rao et al. · The Lancet Infectious Diseases · 2018 · 726 citations · Full text